FDA approves Pluvicto for progressive, PSMA-Positive metastatic CRPC March 24, 2022 The FDA has approved lutetium Lu 177 vipivotide tetraxetan for the treatment of adult patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have previously received other anticancer therapies.To read the full story, click here. Source: Kristi Rosa - OncLive About Prostate Cancer Advanced Prostate Cancer Prostate Cancer News Treatment Options More for you
The FDA has approved lutetium Lu 177 vipivotide tetraxetan for the treatment of adult patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have previously received other anticancer therapies.To read the full story, click here. Source: Kristi Rosa - OncLive
Complete the Survey
